Siemens Healthineers and The Queen’s Health Systems1, Hawai‘i’s largest private health care provider and its largest private employer, have entered…
Browsing: News
GE HealthCare recently announced via a press release that its Genesis portfolio, with cloud-enabled software as a service (SaaS) solutions…
The patent protects the company’s proprietary system for determining current or future clinical or laboratory values directly from non-invasive medical images such as ultrasound.
MinXray’s Impact System, a complete wireless digital X-ray system, is one of three portable X-ray units in the second round of testing by NASA for future human exploration missions.
The collaboration aims to develop a unique robotic system capable of performing a comprehensive range of elective and emergency neurovascular procedures, including treatment for strokes and aneurysms.
Tempus AI Inc., a technology company leading the adoption of AI to advance precision medicine, has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device’s capabilities for cardiac MR image analysis.
Mindray, a global leader in healthcare technologies and solutions specializing in patient monitoring, anesthesia, and ultrasound, has announced a deepened…
GE HealthCare recently announced the launch of the Voluson Performance series, the latest addition to its women’s health ultrasound portfolio. Designed to deliver detailed imaging and simplify workflow with artificial intelligence (AI) and automation tools, the new Voluson Performance 18 and 16 offers clinicians modern, innovative technology to assist with efficient care across a wide range of applications, a press release states.
FDA’s Center for Drug Evaluation and Research, Office of New Drugs has accepted a Letter of Intent for the qualification of Liver Stiffness Measurement by Vibration-Controlled Transient Elastography as a reasonably likely surrogate endpoint for clinical trials in adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (scarring).
ScanLab’s breakthrough SNR Calculator overcomes these limitations by prospectively calculating the true SNR outcome based on the user’s prescribed slices. This allows for the creation of quantitative SNR values that account for all parameter adjustments and physical factors present within the MRI environment.
